---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-107278"
form_type: "8-K"
ticker: "ANTX"
cik: "0001880438"
company_name: "AN2 Therapeutics, Inc."
filed_at: "2025-08-12T23:59:59+00:00"
generated_at: "2026-05-17T14:53:27.469755+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# AN2 Therapeutics Q2 net loss narrows to $6.5M; Chagas Phase 1 dosing underway; cash runway into 2028

## Summary
- Net loss of $6.5M vs $14.4M in Q2 2024; R&D expenses down to $3.2M from $12.1M.
- Cash, cash equivalents, and investments of $71.2M; operations funded into 2028.
- Phase 1 FIH trial for Chagas drug AN2-502998 dosing started; Phase 2 planned for 2026.
- Melioidosis observational study showed ~40% 90-day mortality; seeking U.S. government funding for Phase 2.
- Two oncology development candidates (ENPP1 and PI3Kα) expected within 12 months.

## SEC filing metadata
- accession: 0000950170-25-107278
- form_type: 8-K
- ticker: ANTX
- cik: 0001880438
- company_name: AN2 Therapeutics, Inc.
- filed_at: 2025-08-12T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1880438/000095017025107278/0000950170-25-107278-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1880438/000095017025107278/antx-20250812.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-107278
- JSON: https://secwatch.observer/filing/0000950170-25-107278.json
- Plain text: https://secwatch.observer/filing/0000950170-25-107278.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.